<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544113/" ref="ordinalpos=2897&amp;ncbi_uid=5694190&amp;link_uid=PMC3544113" image-link="/pmc/articles/PMC3544113/figure/F1/" class="imagepopup">Figure 1.  From: Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy. </a></div><br /><div class="p4l_captionBody"><b>Main deregulated signaling pathways in PMBCL.</b> Shown are the main activation cascades of JAK-STAT and NF-ÎºB signaling. Alternative pathway activation exists. Known gene alterations leading to constitutive pathway activity in PMBCL are shown in color. Reprinted from Steidl and Gascoyne9 by permission of the American Society of Hematology.</div></div>